Cargando…

NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab

The NRG Oncology/NSABP B-47 menstrual history (MH) study examined trastuzumab effects on menstrual status and associated circulating reproductive hormones. MH was evaluated by questions related to hysterectomy, oophorectomy, and reported menstrual changes. Pre/perimenopausal women were assessed at e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ganz, Patricia A., Cecchini, Reena S., Fehrenbacher, Louis, Geyer, Charles E., Rastogi, Priya, Crown, John P., Thirlwell, Michael P., Ellison, David M., Boileau, Jean-Francois, Flynn, Patrick J., Jeong, Jong-Hyeon, Mamounas, Eleftherios P., Wolmark, Norman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137688/ https://www.ncbi.nlm.nih.gov/pubmed/34016989 http://dx.doi.org/10.1038/s41523-021-00264-2

Ejemplares similares

Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831
por: Pogue-Geile, Katherine L, et al.
Publicado: (2020)

Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination
por: Swain, Sandra M., et al.
Publicado: (2019)

Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trial
por: Advani, Pooja P., et al.
Publicado: (2023)

Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35
por: Henry, N. Lynn, et al.
Publicado: (2021)

Toxicity Index, patient-reported outcomes, and persistence of breast cancer chemotherapy-associated side effects in NRG Oncology/NSABP B-30
por: Henry, N. Lynn, et al.
Publicado: (2022)

MAF Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice
por: Paterson, Alexander H G, et al.
Publicado: (2021)

Health‐related quality of life outcomes after neoadjuvant chemoradiotherapy for rectal cancer in NRG Oncology/NSABP R‐04
por: Ganz, Patricia A., et al.
Publicado: (2022)

25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1
por: Amir, Eitan, et al.
Publicado: (2012)

Erratum to: 25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1
por: Amir, Eitan, et al.
Publicado: (2012)

NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2(+) breast cancer
por: Jacobs, Samuel A., et al.
Publicado: (2019)

Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer
por: Jacobs, Samuel A., et al.
Publicado: (2020)

Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology)
por: Kim, S Rim, et al.
Publicado: (2018)

Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial
por: Calsavara, Vinicius F., et al.
Publicado: (2023)

Patient‐reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancer
por: Conte, PierFranco, et al.
Publicado: (2020)

21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer
por: Geyer, Charles E., et al.
Publicado: (2018)

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
por: Loibl, Sibylle, et al.
Publicado: (2022)

Talking numbers: how women and providers use risk scores during and after risk counseling – a qualitative investigation from the NRG Oncology/NSABP DMP-1 study
por: Blakeslee, Sarah B, et al.
Publicado: (2023)

Pathologic Complete Response of HER-2 Neu-Positive Invasive Ductal Carcinoma and Ductal Carcinoma In Situ following Neoadjuvant Chemotherapy plus Trastuzumab: A Case Report and Review of Literature
por: Gunia, Sommer R., et al.
Publicado: (2012)

Primary chemotherapy for operable breast cancer: the NSABP experience
por: Bear, HD
Publicado: (2005)

Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer
por: Denkert, Carsten, et al.
Publicado: (2023)

Evaluation of three APBI techniques under NSABP B‐39 guidelines
por: Scanderbeg, Daniel, et al.
Publicado: (2009)

Recruitment practices for U.S. minority and underserved populations in NRG oncology: Results of an online survey()
por: Cook, Elise D., et al.
Publicado: (2018)

Neoadjuvant nab-paclitaxel in the treatment of breast cancer
por: Ueno, Naoto T., et al.
Publicado: (2016)

Four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (NSABP-B27) with concomitant trastuzumab as neoadjuvant therapy for high-risk, early-stage, HER2-positive breast cancer patients
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2018)

Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance
por: Upton, Rosalynd, et al.
Publicado: (2021)

Prophylactic Evidence of MSCs-Derived Exosomes in Doxorubicin/Trastuzumab-Induced Cardiotoxicity: Beyond Mechanistic Target of NRG-1/Erb Signaling Pathway
por: Ebrahim, Nesrine, et al.
Publicado: (2022)

Effects of RET, NRG1 and NRG3 Polymorphisms in a Chinese Population with Hirschsprung Disease
por: Yang, Dehua, et al.
Publicado: (2017)

ADAM10 and ADAM17: New Players in Trastuzumab Resistance
por: Duffy, Michael J., et al.
Publicado: (2014)

NRG-1 talks back to neurons
por: LeBrasseur, Nicole
Publicado: (2003)

NRG1 fusions in breast cancer
por: Howarth, Karen D., et al.
Publicado: (2021)

Expression of NRG1 and its receptors in human bladder cancer
por: Forster, J A, et al.
Publicado: (2011)

Back signaling by the Nrg-1 intracellular domain
por: Bao, Jianxin, et al.
Publicado: (2003)

Novel molecular changes induced by Nrg1 hypomorphism and Nrg1-cannabinoid interaction in adolescence: a hippocampal proteomic study in mice
por: Spencer, Jarrah R., et al.
Publicado: (2013)

Identification of Novel CDH1-NRG2α and F11R-NRG2α Fusions in NSCLC Plus Additional Novel NRG2α Fusions in Other Solid Tumors by Whole Transcriptome Sequencing
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2020)

Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10
por: Abraham, Jame, et al.
Publicado: (2019)

Clinical relevance of the 21-gene Recurrence Score(®) assay in treatment decisions for patients with node-positive breast cancer in the genomic era
por: Mamounas, Eleftherios P., et al.
Publicado: (2018)

Fine Mapping of the NRG1 Hirschsprung's Disease Locus
por: Tang, Clara Sze-Man, et al.
Publicado: (2011)

NRG1 variant effects in patients with Hirschsprung disease
por: Gunadi, et al.
Publicado: (2018)

Nrg1 Intracellular Signaling Is Neuroprotective upon Stroke
por: Navarro-González, Carmen, et al.
Publicado: (2019)

Spironolactone is an antagonist of NRG1‐ERBB4 signaling and schizophrenia‐relevant endophenotypes in mice
por: Wehr, Michael C, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bn75325vc7gia6ldf87c4ee1sv